- Home
- WGRX vs UNCY Comparison
WGRX vs UNCY Comparison
Compare WGRX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- UNCY
- Stock Information
- Founded
- WGRX 2022
- UNCY 2016
- Country
- WGRX United States
- UNCY United States
- Employees
- WGRX N/A
- UNCY N/A
- Industry
- WGRX Other Pharmaceuticals
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- UNCY Health Care
- Exchange
- WGRX Nasdaq
- UNCY Nasdaq
- Market Cap
- WGRX 63.6M
- UNCY 56.4M
- IPO Year
- WGRX 2025
- UNCY 2021
- Fundamental
- Price
- WGRX $0.82
- UNCY $4.09
- Analyst Decision
- WGRX
- UNCY Strong Buy
- Analyst Count
- WGRX 0
- UNCY 4
- Target Price
- WGRX N/A
- UNCY $63.75
- AVG Volume (30 Days)
- WGRX 5.2M
- UNCY 476.3K
- Earning Date
- WGRX 08-26-2025
- UNCY 08-14-2025
- Dividend Yield
- WGRX N/A
- UNCY N/A
- EPS Growth
- WGRX N/A
- UNCY N/A
- EPS
- WGRX N/A
- UNCY N/A
- Revenue
- WGRX $36,907,109.00
- UNCY N/A
- Revenue This Year
- WGRX N/A
- UNCY N/A
- Revenue Next Year
- WGRX N/A
- UNCY $1,178.98
- P/E Ratio
- WGRX N/A
- UNCY N/A
- Revenue Growth
- WGRX N/A
- UNCY N/A
- 52 Week Low
- WGRX $0.62
- UNCY $2.83
- 52 Week High
- WGRX $7.04
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- UNCY 40.82
- Support Level
- WGRX N/A
- UNCY $3.86
- Resistance Level
- WGRX N/A
- UNCY $4.97
- Average True Range (ATR)
- WGRX 0.00
- UNCY 0.30
- MACD
- WGRX 0.00
- UNCY 0.04
- Stochastic Oscillator
- WGRX 0.00
- UNCY 20.72
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.